MAY 28TH, 2020
Join Gerald Platteau, Senior Application Development Engineer, for a webinar on Amsphere A3, our alkali stable protein A resin that has shown to be an effective capture purification step for a wide range of antibody fragment variants.
New biological modalities are rapidly emerging as candidate therapeutics for challenging disease targets. Stepping away from the classical antibody constructs comes with challenges, as modifications are necessary to develop an effective and robust process on an accelerated timeline.
Amsphere A3, an alkali stable protein A resin, has shown to be an effective capture purification step for a wide range of antibody fragment variants.
In this webinar, we will review the following items for fragment purification:
- Binding mechanism between the engineered C domain of the Amsphere™ A3 protein A (PrA) ligand and a VHH single-domain antibody (sdAb)
- Protein A – Ab fragment complex structure via x-ray crystallography
- CH1 binding capacity and purification case study results
- Additional data on mAb variants